Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4

Mostrar otras versiones (1)
Detalles Bibliográficos
Autores principales: Holmgaard, Rikke B, Zamarin, Dmitriy, Munn, David H, Wolchok, Jedd D, Allison, James P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991256/
http://dx.doi.org/10.1186/2051-1426-1-S1-P77
_version_ 1782312402417614848
author Holmgaard, Rikke B
Zamarin, Dmitriy
Munn, David H
Wolchok, Jedd D
Allison, James P
author_facet Holmgaard, Rikke B
Zamarin, Dmitriy
Munn, David H
Wolchok, Jedd D
Allison, James P
author_sort Holmgaard, Rikke B
collection PubMed
description
format Online
Article
Text
id pubmed-3991256
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39912562014-05-05 Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4 Holmgaard, Rikke B Zamarin, Dmitriy Munn, David H Wolchok, Jedd D Allison, James P J Immunother Cancer Poster Presentation BioMed Central 2013-11-07 /pmc/articles/PMC3991256/ http://dx.doi.org/10.1186/2051-1426-1-S1-P77 Text en Copyright © 2013 Holmgaard et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Presentation
Holmgaard, Rikke B
Zamarin, Dmitriy
Munn, David H
Wolchok, Jedd D
Allison, James P
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4
title Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4
title_full Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4
title_fullStr Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4
title_full_unstemmed Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4
title_short Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4
title_sort indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor t cell immunotherapy targeting ctla-4
topic Poster Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991256/
http://dx.doi.org/10.1186/2051-1426-1-S1-P77
work_keys_str_mv AT holmgaardrikkeb indoleamine23dioxygenaseisacriticalresistancemechanisminantitumortcellimmunotherapytargetingctla4
AT zamarindmitriy indoleamine23dioxygenaseisacriticalresistancemechanisminantitumortcellimmunotherapytargetingctla4
AT munndavidh indoleamine23dioxygenaseisacriticalresistancemechanisminantitumortcellimmunotherapytargetingctla4
AT wolchokjeddd indoleamine23dioxygenaseisacriticalresistancemechanisminantitumortcellimmunotherapytargetingctla4
AT allisonjamesp indoleamine23dioxygenaseisacriticalresistancemechanisminantitumortcellimmunotherapytargetingctla4

Ejemplares similares